Once-weekly Glucagon-like Peptide-1 Receptor Agonists
The Journal of Family Practice. 2018 June;67(6):
This supplement is supported by funding from Novo Nordisk Inc.
May 30, 2018|Family Medicine
This supplement provides an overview of the role of once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in type 2 diabetes (T2D).
Topics include:
- Burden of illness in patients with T2D
- Pharmacokinetic properties and the mode and mechanism of action of GLP-1 RAs
- Safety and clinical efficacy of GLP-1 RAs
- Implications of cardiovascular outcomes trials in T2D